IST:GENIL's PB Ratio is ranked worse than 74.11% of 923
companies
in the Drug Manufacturers industry
Industry Median: 1.81
vs IST:GENIL: 3.56
During the past 12 months, Gen Ilac Veglik Urunlerinayi ve Ticaret AS's average Book Value Per Share Growth Rate was 40.90% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 28.10% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 82.10% per year.
During the past 8 years, the highest 3-Year average Book Value Per Share Growth Rate of Gen Ilac Veglik Urunlerinayi ve Ticaret AS was 172.60% per year. The lowest was 28.10% per year. And the median was 125.10% per year.
Back to Basics: PB Ratio
Gen Ilac Veglik Urunlerinayi ve Ticaret AS (IST:GENIL) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Gen Ilac Veglik Urunlerinayi ve Ticaret AS PB Ratio Related Terms
Gen Ilac Veglik Urunlerinayi ve Ticaret AS PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gen Ilac Veglik Urunlerinayi ve Ticaret AS PB Ratio Chart
Gen Ilac Veglik Urunlerinayi ve Ticaret AS Annual Data
For the Drug Manufacturers - Specialty & Generic subindustry, Gen Ilac Veglik Urunlerinayi ve Ticaret AS's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gen Ilac Veglik Urunlerinayi ve Ticaret AS PB Ratio vs Drug Manufacturers Industry
Gen Ilac Veglik Urunlerinayi ve Ticaret AS PB Ratio Calculation
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Gen Ilac Veglik Urunlerinayi ve Ticaret AS (IST:GENIL) has a PB Ratio of 3.56 as of Jun. 29, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Gen Ilac Veglik Urunlerinayi ve Ticaret AS and its competitors. This is 10% below median its historical median of 3.95. Over the past decade, Gen Ilac Veglik Urunlerinayi ve Ticaret AS's PB Ratio has ranged from 1.76 to 8.55. According to the industry distribution chart, Gen Ilac Veglik Urunlerinayi ve Ticaret AS ranks #684 out of 923 companies in the Drug Manufacturers industry, placing it in the top 74.1%.
Is Gen Ilac Veglik Urunlerinayi ve Ticaret AS's PB Ratio too high?
Gen Ilac Veglik Urunlerinayi ve Ticaret AS's current PB Ratio of 3.56 is 10% below median its 10-year median of 3.95. Over the past 10 years, this metric has ranged from a low of 1.76 to a high of 8.55. The Drug Manufacturers industry median PB Ratio is 1.81. Gen Ilac Veglik Urunlerinayi ve Ticaret AS's value of 3.56 is 96.7% above this industry median. Based on the distribution chart, Gen Ilac Veglik Urunlerinayi ve Ticaret AS ranks #684 out of 923 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Gen Ilac Veglik Urunlerinayi ve Ticaret AS has a GF Score™ of 86/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Gen Ilac Veglik Urunlerinayi ve Ticaret AS's PB Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Gen Ilac Veglik Urunlerinayi ve Ticaret AS ranks #684 out of 923 companies for PB Ratio. This places Gen Ilac Veglik Urunlerinayi ve Ticaret AS in the lower half of its industry. The industry median PB Ratio is 1.81. Gen Ilac Veglik Urunlerinayi ve Ticaret AS's value of 3.56 is 96.7% above this benchmark. Historically, Gen Ilac Veglik Urunlerinayi ve Ticaret AS's own PB Ratio has ranged from 1.76 to 8.55 over the past decade. While the company's 10-year median is 3.95 vs. the industry median of 1.81, Gen Ilac Veglik Urunlerinayi ve Ticaret AS has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.81, based on 923 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Gen Ilac Veglik Urunlerinayi ve Ticaret AS's current PB Ratio of 3.56 is 96.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Gen Ilac Veglik Urunlerinayi ve Ticaret AS and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.81 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gen Ilac Veglik Urunlerinayi ve Ticaret AS's current PB Ratio is 3.56, which is 10% below median its own 10-year median of 3.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gen Ilac Veglik Urunlerinayi ve Ticaret AS stock overvalued right now?
Based on GuruFocus' analysis, Gen Ilac Veglik Urunlerinayi ve Ticaret AS (IST:GENIL) is currently considered Modestly Overvalued. The stock's GF Value™ is ₺8.12, compared to a current price of ₺9.32 — trading 14.8% above its estimated fair value. The current PB Ratio is 3.56, which is 10% below median its 10-year median of 3.95 and 96.7% above the Drug Manufacturers industry median of 1.81. Gen Ilac Veglik Urunlerinayi ve Ticaret AS's overall GF Score™ is 86/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Gen Ilac Veglik Urunlerinayi ve Ticaret AS (IST:GENIL), the current PB Ratio is 3.56 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gen Ilac Veglik Urunlerinayi ve Ticaret AS (IST:GENIL) Overvalued in 2026?
Based on GuruFocus' analysis, Gen Ilac Veglik Urunlerinayi ve Ticaret AS stock appears to be overvalued.
The current stock price of ₺9.32 is trading 14.8% above its estimated GF Value™ of ₺8.12.
GuruFocus considers Gen Ilac Veglik Urunlerinayi ve Ticaret AS to be Modestly Overvalued.
Key valuation signals for IST:GENIL:
PB Ratio: 3.56 (10% below median its 10-year median of 3.95)
GF Value™: ₺8.12 vs. price of ₺9.32 (14.8% above fair value)
Industry Position: 96.7% above the Drug Manufacturers median (#684 of 923)
No single metric tells the full story. See the IST:GENIL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gen Ilac Veglik Urunlerinayi ve Ticaret AS Business Description
Gen Ilac Ve Saglik Urunleri Sanayi ve Ticaret AS is a specialty pharmaceuticals company in Turkey. Its locally manufactured products include Cajex, Contra-K, Epamor, Genkort, Ilopera, among others, while imported products include AvonexPEN, Plegridy, Tecfidera, Regen-D among others.
86GF Score
Get the complete analysis for IST:GENIL
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IST:GENIL has been successfully added to your 
